SEC Form 4 · accession 0001209191-15-078168
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul M Silva
Officer — SVP & Corp Controller
Period of report
Oct 30, 2015
Accepted (ET)
Nov 3, 2015 · 5:56 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Oct 30, 2015 | S | 400 | $123.37 | D | 17,975 | D | |
| Common StockF2,F4 | Oct 30, 2015 | S | 900 | $124.98 | D | 17,075 | D | |
| Common StockF2,F5 | Oct 30, 2015 | S | 1,638 | $126.04 | D | 15,437 | D | |
| Common StockF2,F6 | Oct 30, 2015 | S | 500 | $126.64 | D | 14,937 | D | |
| Common Stock | holding | — | — | — | 169 | I | 401(k) |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1.
- F2Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F3Open market sales reported on this line occurred at a weighted average price of $123.37 (range $123.14 to $123.83).
- F4Open market sales reported on this line occurred at a weighted average price of $124.98 (range $124.38 to 125.33).
- F5Open market sales reported on this line occurred at a weighted average price of $126.04(range $125.42 to $126.39).
- F6Open market sales reported on this line occurred at a weighted average price of $126.64 (range $126.52 to $126.73).